Release Date: 28/08/16 01:22 Summary: Appendix 4E and Annual Report to shareholders-YBR.AX Price Sensitive: Yes Download Document 5.07MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%